Akèy › Limfòm Gwo Selil Anaplastik
Etid klinik pou Limfòm Gwo Selil Anaplastik ap rekrite nan Etazini
15 etid pou Limfòm Gwo Selil Anaplastik ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- Durham, NC4 etid
- St. Louis, MO4 etid
- Atlanta, GA4 etid
- Rochester, MN4 etid
- Houston, TX4 etid
- Columbus, OH3 etid
- Baldwin Park, CA3 etid
- Philadelphia, PA3 etid
- Seattle, WA3 etid
- New York City, NY3 etid
- Boston, MA3 etid
Pa eta
- Arizona3 etid
- Florid3 etid
- Georgia4 etid
- Illinois3 etid
- Kalifòni4 etid
- Maryland3 etid
- Massachusetts3 etid
- Minnesota4 etid
- Missouri4 etid
- New Jersey3 etid
- New York5 etid
- North Carolina5 etid
- Ohio3 etid
- Pennsylvania4 etid
- Texas5 etid
- Washington3 etid
- Wisconsin3 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06561048A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Ap rekriteFaz 1/2
Jiska laj 25 · Tout sèks · Mizajou Sep 25, 2026 · NCT04094610Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
Ap rekriteFaz 3
Laj 18 a 75 · Tout sèks · Mizajou Sep 14, 2026 · NCT06724237A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)
Ap rekriteFaz 1
Laj 18 a 120 · Tout sèks · Mizajou Aug 24, 2026 · NCT07055477Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL)
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Aug 6, 2026 · NCT07750886Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas
Ap rekriteFaz 1
Laj 12 a 75 · Tout sèks · Mizajou Jul 20, 2026 · NCT06176690Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 1, 2026 · NCT06508463Registry of Older Patients With Cancer
Ap rekriteEtid obsèvasyon
Laj 65 ak plis · Tout sèks · Mizajou Jun 29, 2026 · NCT01137825A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jun 10, 2026 · NCT03017820Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Ap rekriteFaz 2Volontè an sante akeyi
6 Months · Tout sèks · Mizajou May 29, 2026 · NCT04195633A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou May 26, 2026 · NCT07001384Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL
Ap rekriteFaz 2
Laj 1 a 39 · Tout sèks · Mizajou May 20, 2026 · NCT07013565A Registry for People With T-cell Lymphoma
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou May 20, 2026 · NCT05978141Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Apr 3, 2026 · NCT05544968Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Ap rekriteEtid obsèvasyon
Laj 18 a 120 · Tout sèks · Mizajou Oct 27, 2025 · NCT01137643Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.